FDA Shows Caution, Delays Trump-Backed Fast-Track Drugs Over Risks

Benzinga_recent_news01-15

The U.S. Food and Drug Administration (FDA) reportedly delayed reviews of several drugs selected for the Trump administration’s new fast-track approval program, after agency scientists raised concerns...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment